Abstract
Smoking and obesity remain the two most prevalent reversible health risk factors in Singapore. Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RAs) are established therapies for diabetes mellitus (DM) and obesity. Recently, they have also shown promise in aiding smoking cessation. Once more robust studies of GLP-1 RAs support this finding, they may play an integral role in reducing the health impact of both risk factors in Singapore.
Reference14 articles.
1. National Population Health Survey 2020 and National Population Health Survey 2021. Epidemiology & Disease Control Division and Policy, Research & Surveillance Group Ministry of Health and Health Promotion Board, Singapore.
2. White paper on Healthier SG. Ministry of Health, Singapore. September 2022. Available online at: https://file.go.gov.sg/healthiersg-whitepaper-pdf.pdf [Accessed on 9th December 2022]
3. Use of pharmacotherapy in obesity management. Tham KW. The Singapore Family Physician Vol 4 8(7) Jul-Sep 2022:30-35
4. The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice
5. Tuesta LM, Chen Z, Duncan A, Fowler CD, Ishikawa M, Lee BR, Liu XA, Lu Q, Cameron M, Hayes MR, Kamenecka TM, Pletcher M, Kenny PJ. GLP-1 acts on habenular avoidance circuits to control nicotine intake. Nat Neurosci. 2017 May;20(5):708-716. doi: 10.1038/nn.4540. Epub 2017 Apr 3. PMID: 28368384; PMCID: PMC5541856.